Skip to main content
Premium Trial:

Request an Annual Quote

BioVision Sells ImVision Spin-Off to Swiss Investment Shop

NEW YORK, May 3 (GenomeWeb News) - Germany-based peptide-identification company BioVision has sold its ImVision spin-off to Swiss life-science investment company Nextech, the company said today.


ImVision develops immunotherapeutics based on its Modular-Antigen-Transport technology to treat allergic diseases, infectious diseases, and "possibly" cancer. The technology was developed by BioVision and the Swiss Institute of Allergy and Asthma Research.


As a biological research organization, BioVision offers "mainly" services for peptide biomarker discovery "but pursues also selected in-house research projects," BioVision Chief Business Officer Rainer Voegeli said in a statement. "It is the policy of BioVision to partner or to sell projects which have reached development status. ImVision is the first, others will follow."


Financial terms of the sale were not disclosed.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.